Cardiology

Patients in the intensive blood pressure treatment group had a 19% lower risk of developing mild cognitive impairment compared to those given standard treatment, according to the SPRINT MIND study.

Patient history includes right heart failure due to sinus venosus defect with anomalous right pulmonary venous return; surgical repair performed ca 2006.

Does caffeine increase or decrease the risk of new onset AF? Find out with our T/F quiz on results of a new meta-analysis.

The PocketECG Cardiac Rehabilitation System provides electrocardiography (ECG) monitoring and alerts during cardiac rehabilitation.

Phase 2a clinical trial commences for repurposed drug, SOM3355, for the treatment of Huntington’s disease.

A review of literature on depression and anxiety in patients with heart failure reports that 21.5% have depressive symptoms and 19% meet the criteria for a depressive disorder—2 to 3 times higher than rates in the general population.

The paradigm of obesity is complex and requires a multi-disciplinary approach, but it is one of the most gratifying experiences for both the physicians and patient when they see the results of weight loss.

Results showed that participants with doctor-diagnosed asthma had a 38% increased risk of developing AF compared to those without asthma.

Certain lots of the therapy, distributed under the Actavis label in the US, have been detected to have trace amounts of probably human carcinogen NDMA.

The Surpass Streamline stent is approved to treat unruptured large and giant wide-neck intracranial aneurysms.

Abbott’s updated MitraClip is a catheter-bases system that provides an alternative to open heart surgery for repairing mitral regurgitation.

A few months after performing a first-of-its-kind procedure in the US, members of the John Ochsner Heart and Vascular Institute surgical team explore what led to the surgical success.

The Cleveland Clinic’s pioneer of minority programs plans to end health disparity.

Pulmonary arterial hypertension is a rare, but deadly complication of systemic lupus erythematosus. French investigators sought to identify clinical features of patients with both. 

A study in the VA system found that only 19% of patients diagnosed with pulmonary hypertension received a PDE5 inhibitor prescription consistent with clinical guidelines.

The HVAD system is the only approved LVAD approved for implant via thoracotomy or median sternotomy.

AF is associated with major disease burden, predominately in the form of cardiovascular comorbidities. As a direct oral anti-coagulant, rivaroxaban has been a proven inhibitor of ischemic stroke risks in patients with AF.

The inverse association between coffee-drinking and all-cause mortality held even for participants with genetic variations affecting caffeine metabolism.

Trials of valbenazine for TD do not find that the treatment adds to cardiovascular disease risks associated with schizophrenia or the cardiovascular complications of antipsychotics.

In a comparison of canagliflozin to other SGLT-2 inhibitors and anti-hyperglycemic therapies, the drug was found to decrease hospitalization from heart failure risk, and carry no extra risk for leg or foot amputation.

The supplement included data from decade-long noninferiority PRECISION trial, which revealed safety data for using celecoxib in conjunction with aspirin.

Updated data on MoveDMD, a phase 2, open-label extension trial of edasalonexent in boys diagnosed with Duchenne muscular dystrophy (DMD), reports positive results.

How some of the most recent trial analysis narrows the clinical scope of GLP-1 and SGLT-2 targeting therapies.

Cardiovascular disease is the leading cause of death in women. And yet, the crux of concern for disease risk is designated to male patients.

Is there a relationship between polycystic ovary syndrome and diabetes? And if so, what are the variations in female patients?

During the first 12 weeks of study, the investigated therapy had also reduced patient hypoglycemia event rates by 23% and low blood sugar event rates by 26% versus comparative therapy.

New study finds that noninvasive assessment of CAD with CCTA may help reclassify risk and predict MACE in asymptomatic atherosclerosis.

Empagliflozin has reported positive outcomes in renal conditions and heart failure in T2D patients. Now what?

The absolute risk reduction for patients with diabetes and recent ACS was 2.3% when on the PCSK9 inhibitor plus statin therapy.

Post-hoc analyses from the EMPA-REG OUTCOME study found consistent benefits for the therapy in comorbidities versus placebo.